Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
3 pending office actions • 1 art units • 3 examiners • 0 of 3 (0%) have an AI response strategy ready
Ronawk Inc. has 3 pending office actions in the Biotechnology & Pharmaceuticals technology area. These actions are all located within 1 distinct art unit, indicating a specific technical focus for the company's current filings. The company is working with 3 distinct examiners, so each of the 3 pending actions is being reviewed by a different official.
VIJAYARAGHAVAN, JAGAMYA NMN is the busiest examiner for the company, with 1 pending office action. This 1 action is part of the 3 total pending actions currently active. The concentration of all 3 actions in 1 art unit, despite the involvement of 3 distinct examiners, indicates that the company's innovations are being evaluated by a single specialized group within the patent office. For practitioners, this means that while the technical standards of the art unit may be consistent, they must still account for the individual preferences of 3 different examiners. Managing these 3 pending office actions requires a strategy that addresses the specific requirements of the Biotechnology & Pharmaceuticals field as interpreted by 3 distinct reviewers. The presence of 3 examiners within a single art unit is a notable feature of this portfolio.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Double-patenting + other | 2 (67%) |
| Multi-statute (no §101) | 1 (33%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| VIJAYARAGHAVAN, JAGAMYA NMN | 1 | 62.5% | +49.3% |
| RAHMAN, MASUDUR | 1 | 72.7% | +31.7% |
| CORDAS, EMILY ANN | 1 | 50.8% | +57.3% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18726687 | Applications of Biological Block Platform | RAHMAN, MASUDUR | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 3 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18726666 | INTERLOCKING POROUS HYDROGEL BLOCKS | VIJAYARAGHAVAN, JAGAMYA NMN | — |
| 18726687 | Applications of Biological Block Platform | RAHMAN, MASUDUR | — |
| 18726671 | Cell Cultivation Methodology | CORDAS, EMILY ANN | — |
| Art Unit | Apps |
|---|---|
| 1632 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18726666 | INTERLOCKING POROUS HYDROGEL BLOCKS | VIJAYARAGHAVAN, JAGAMYA NMN | — | §103§112DPOther | Non-Final OA | — | Pending | Jul 03, 2024 |
| 18726687 | Applications of Biological Block Platform | RAHMAN, MASUDUR | 1632 | §103§112 | Non-Final OA | — | Pending | Jul 03, 2024 |
| 18726671 | Cell Cultivation Methodology | CORDAS, EMILY ANN | — | §102§103§112DP | Non-Final OA | — | Pending | Jul 03, 2024 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial